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As a relatively safe outpatient procedure, radioembolization can potentially be used to treat
any type of tumor within the liver, primary or metastatic. The safety and effectiveness of
radioembolization in the treatment of hepatocellular carcinoma (HCC) and metastatic col-
orectal cancer (mCRC) has ledmany groups to explore its application in other malignancies.
Moreover, other organs, such as the lungs and kidneys, have been explored as targets for
therapy. Although themost data for radioembolization is related to HCC andmCRC, there is
increasing experience and data regarding metastatic disease to the liver for other primary
tumors.We review the current state of liver-directed therapywith radioembolization outside
of HCC and mCRC, including metastatic neuroendocrine, breast, and melanoma, as well
as limited experiences with other primary malignancies. Applications of radioembolization
related to these other cancers and new trends and future directions will be discussed.With
increasing use and availability of radioembolization, it promises to serve an expanding role
in the repertoire of tools available for treating and managing oncologic disease.
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INTRODUCTION
As a relatively safe outpatient procedure, radioembolization can
potentially be used to treat any type of tumor within the liver,
primary or metastatic. The safety and effectiveness of radioem-
bolization in the treatment of hepatocellular carcinoma (HCC)
and metastatic colorectal cancer (mCRC) has led many groups
to explore its application in other malignancies. Moreover, other
organs, such as the lungs and kidneys, have been explored as tar-
gets for therapy. Although the most data for radioembolization is
related to HCC and mCRC, there is increasing experience and data
regarding metastatic disease to the liver for other primary tumors.
We review the current state of liver-directed therapy with radioem-
bolization outside of HCC and mCRC, including metastatic neu-
roendocrine, breast, and melanoma, as well as limited experiences
with other primary malignancies. Applications of radioemboliza-
tion related to these other cancers and new trends and future
directions will be discussed. With increasing use and availability of
radioembolization, it promises to serve an expanding role in the
repertoire of tools available for treating and managing oncologic
disease.
RADIOEMBOLIZATION IN LIVER METASTASES OTHER THAN
mCRC
Radioembolization has a proven role in the treatment liver metas-
tases from mCRC, however, increasing evidence shows its efficacy
in several other primary tumor types. Liver tumors derive relatively
more of their blood supply from the hepatic artery than adjacent
normal liver, which is primarily perfused by the portal vein. As
such, radioembolization may have the potential to treatment a
wide variety of liver metastases.
Due to the exploratory nature of treatment of liver metas-
tases beyond mCRC, many studies employ radioembolization only
after failing standard treatment or in cases where certain crite-
ria for standard treatment are not met. Large or multiple lesions
may preclude surgical resection, with radioembolization offered
as a means to control disease progression. In patients who have
failed systemic therapies or cannot tolerate further chemotherapy,
radioembolization may be offered as a salvage therapy. As such,
randomized trials of radioembolization vs. standard therapy are
lacking. Nevertheless, several published series of radioemboliza-
tion of hepatic metastases have shown promising results. Here, we
discuss the current state of radioembolization for liver metastases
beyond mCRC.
NEUROENDOCRINE TUMOR METASTASES
As a whole, neuroendocrine tumors (NETs) are rare, compris-
ing approximately 0.5% of malignancies. They are often indolent,
presenting with symptoms due to hormonal activity or as a result
of invasion of local structure from either the primary tumor or
metastases. Forty to ninety percent of patients with NETs will have
liver metastases at the time of diagnosis (1). These patients have a
significantly worse prognosis than those without liver involvement
having a 5-year survival of 0–20%.
Surgical resection remains the definitive treatment for NET
metastasis. However, due to their often indolent course, patients
often present with large and/or multiple lesions, precluding surgi-
cal resection. For this reason and in patients who are otherwise not
surgical candidates, other forms of therapy are being investigated.
NETs are highly vascular, with a great portion of blood supply
from the hepatic artery as compared to the adjacent normal liver
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tissue, which is pre-dominantly supplied by the portal vein. As
a result, intra-arterial therapies are being investigated, including
radioembolization with Y-90 microspheres.
However, limitations in performing a retrospective review
of radioembolization in metastatic NET arise from the het-
erogeneous methods employed in the various published small-
scale series. While large scale, controlled trials of transarter-
ial chemoembolization (TACE) have been performed, radioem-
bolization remains a newer approach and is often performed in
patients who have otherwise failed or have contraindications to
frontline therapies. Many patients have had previous liver resec-
tions or are being treated with various neoadjuvant medications,
which may affect response and potential complications. Even the
criteria utilized for measuring response varies between series,
limiting comparison, and pooling of data. Brown et al. have sug-
gested a framework for reporting of transcatheter treatment of
hepatic malignancies (2), although in the absence of widespread
adoption of such standards, data from smaller case series can-
not be readily aggregated, limiting the ability to draw effective
conclusions.
In order to provide a perspective on efficacy, comparison of
radioembolization to other intra-arterial treatment modalities
such as TACE is useful. Yang et al. reviewed several publica-
tions reporting NET treatment with radioembolization. In their
study, radioembolization patients had an objective response of
63.1% compared to 58.4% of those treated with TACE. The clin-
ical response rates were 85 and 88.5% for radioembolization and
TACE, respectively (1). One and 5-year survival rates for radioem-
bolization patients were 84.7 and 50.5%, while TACE patients were
75 and 30.5%, respectively.
King et al. reported a series of 34 patients treated for NET
metastasis with 22 patients (65%) experiencing complete response
(CR), partial response (PR), or stable disease (SD) by RECIST cri-
teria (3). One patient died within 1 month and the remaining 11
patients showed progressive disease by imaging. The mean sur-
vival was 27.6± 2.3 months. Fourteen patients (41%) died from
progressive metastatic disease at 1–28 months with mean survival
of 14.6± 2.2 months, and 20 patients remained alive at the end of
the study period with mean survival of 36.7± 1.8 months.
Murthy et al. also reported that radioembolization for NET
metastasis can be performed after previous TACE with a median
survival time of 14 months after radioembolization (4). In a mul-
ticenter phase II study with 42 patients of hepatic NET metastases,
Rhee et al. investigated the efficacy and safety of radioemboliza-
tion. They observed that 92 and 94% of patients treated with
glass (TheraSpheres, Nordion Inc.) and resin-microspheres (SIR-
spheres, Sirtex Medical Limited), respectively showed either PR
or SD at 6 months, and median survival was 22 and 28 months,
respectively. Though there remains debate about the use of glass
vs. resin spheres, their study found no significant difference in
survival outcomes (5).
To date, there have been no published controlled trials com-
paring radioembolization to TACE for metastatic NET. Such
trials would provide stronger evidence for providers to choose
radioembolization for metastatic NET. However, current data
shows promise for the modality. Radioembolization may allow
control and possible downstaging of liver metastases, possibly
making patients eligible for other treatment options such as
radiofrequency ablation, liver resection, or liver transplantation.
BREAST CANCER METASTASES
Breast cancer is the most common malignancy in females, with
an estimated lifetime risk of 10–15%. While the overall 5-year
survival is >90% when there is only local occurrence, survival in
patients with metastatic disease is only 3–20% depending on age
and comorbidities (6). Despite advances in treatment, metastatic
breast cancer remains a major cause of morbidity and mortality.
Breast cancer most frequently metastasizes to the skeleton, liver,
lungs, and brain. Among patients with metastases, approximately
5–20% have liver metastases, although autopsy studies suggest the
incidence may be as high as 61% (7). The prognosis of patients with
liver metastases is poor with a median survival time in the range
of 1–20 months. As with other liver malignancies, surgical resec-
tion is considered the only option for cure of breast cancer liver
metastases. Unfortunately,up to 57% of breast cancer patients with
liver disease are found to have disseminated metastases, precluding
surgical intervention (7).
Radioembolization has been explored as a treatment option for
breast cancer metastases, and several studies have been published
describing outcomes. It is usually offered as a salvage treatment
in patients with end-stage disease, history of several previous
systemic therapies, and high incidence of extra-hepatic metas-
tases. Nevertheless disease control rates have been reported as
high as 70–96% (8, 9). Saxena et al. reported a median survival
of 13.6 months after the first radioembolization treatment. While
no control group is available from this study, Wyld et al. reported
an overall survival of only 4.2 months (10) within a total of 145
studied patients with liver metastases from breast cancer treated
with systemic chemotherapy or best supportive care.
Interestingly, radioembolization survival was found to improve
with three identified prognostic factors: extent of replacement
of hepatic parenchyma by tumor (less involvement associated
with increased survival), chemotherapy after radioembolization
(yes vs. no; p= 0.015), and radiological response to treatment
(per RECIST criteria CR/PR vs. SD vs. PD). This suggests that
patients who undergo radioembolization may benefit from further
chemotherapy. For many patients, the side effects of chemother-
apy are difficult to overcome, and given the relative tolerance of
radioembolization, a treatment plan involving the use of radioem-
bolization during a “chemotherapy holiday” can be an attractive
option.
The studies included in this review were again retrospective
case series. The lack of comparative, prospective studies limits any
definitive conclusions on the efficacy of this treatment for this
population. As opposed to other applications, such as colorec-
tal cancer, which primarily metastasize to the liver, breast cancer
often metastasizes beyond the liver. In such patients, radioem-
bolization may not lead to a survival benefit, even if the hepatic
disease is controlled. Further studies, including combinations of
radioembolization therapy with systemic therapy will be necessary
to fully define the role of radioembolization in metastatic breast
cancer.
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UVEAL MELANOMAMETASTASES
Uveal melanoma (UM) is the most common primary intraocular
tumor in adults and has a pre-dilection to metastasize to the liver.
These are often widespread with a poor prognosis, and liver failure
is the primary cause of death in these patients. Given the extent
of disease in this group of patients, surgical resection and other
liver-directed therapies such as thermal ablation are usually not an
option.
The first report of metastatic ocular melanoma treatment came
from Kennedy et al. (11) who reported a retrospective review of
11 patients (6 females, 5 males) receiving 12 treatments. The dura-
tion of time from original diagnosis to radioembolization was a
median of 25.5 months (1–118 months). All patients had bi-lobar
disease and more than four lesions. Three patients died from extra-
hepatic metastases at 2.5, 3, and 18 months post-treatment. One
patient was lost to follow-up. Of the remaining eight patients, one
developed new hepatic lesions at 14 months and was retreated. The
median survival was not reached at end of the study period; how-
ever survival at 1 year was 80%. This compares with a report of the
Collaborative Ocular Melanoma Study (CMOS) Group finding a
median time from diagnosis of metastasis to death of <6 months
and a death rate of 80% at 1 year and 92% at 2 years following
report of melanoma metastasis (12).
Gonsalves et al. reported a series of 32 patients who under-
went radioembolization therapy for UM hepatic metastasis (13).
The median overall survival was 10.0 months, and progression-
free survival of hepatic metastasis was 4.7 months. Patients were
grouped by pre-treatment tumor burden into three categories:
<25% (n= 25), 25–50% (n= 5), and>50% (n= 2). Patients with
tumor burden <25% had longer median overall survival (10.5
vs. 3.9 months, p= 0.0003) and progression-free survival (6.4
vs. 3.0 months, p= 0.03) than patients who had a pre-treatment
tumor burden of 25% or greater. Patients with CR (n= 1), PR
(n= 1), or SD (n= 18) had longer median overall survival (14.7
vs. 4.9 months, p= 0.0006) and progression-free survival (7.9
vs. 3.1 months, p< 0.0001) than patients with tumor progres-
sion (n= 12). Similar to other applications of radioembolization,
self-limiting grade 1–2 systemic toxicities were the most frequent
including fatigue (n= 9), indigestion (n= 2), and abdominal dis-
comfort (n= 5). Grade 3–4 hepatic toxicities were attributed to
tumor progression.
Dhanasekaran et al. reported 12 patients with melanoma, who
failed systemic therapy and were treated with Y-90 radioemboliza-
tion (SIR-Spheres) (14). Overall median survival from the diagno-
sis of liver metastases was 13.9 months (6.2–21.6). Median survival
in patients treated with Y-90 radioembolization was 15.5 months.
The duration of SD by RECIST criteria in patients treated with
Y-90 was found to be 10.10 months with a positive correlation
between progression-free duration and survival (p= 0.05).
Klingenstein et al. reported results from 13 patients. In their
series, pre-treatment hepatic tumor load varied with the major-
ity having tumor load of 25–50% (n= 8) and all were confirmed
to be FDG avid on PET (15). Treatment response after radioem-
bolization was partial in eight patients (62%), stable in two patients
(15%), and progressive in three patients (23%) by RECIST criteria.
After 6 months, of the eight patients still alive, two patients showed
ongoing PR, four patients had SD, and two had progressive disease.
By PET, the response was less positive with only three
patients (23%) showing PR and seven (54%) with progres-
sive disease. Median survival time after radioembolization was
7 months. Patient median survival after diagnosis of metastases
was 19 months (range 4–56). Of note, evaluation method (RECIST
vs. PET criteria) did not show any significant difference in
predicting survival.
OTHER PRIMARY TUMORS
Several investigators have reported experiences in treating liver
metastases from other primary malignancies. The majority of
these are patients with unresectable tumors, chosen on a case by
case basis. Aggregate data on response by RECIST criteria using
either CT, MRI, or by PET suggests promising results. Stuart et al.
reported a cohort of 30 patients with chemo-resistant liver metas-
tases including sarcoma (n= 3), esophageal (n= 2), endometrial
(n= 1), lung (n= 1), ovarian (n= 1), SCC of the anus (n= 1),
and unknown primary (n= 1) as well as colorectal (n= 13) and
breast cancer (n= 7) (16). The 10 patients with liver metastases
from other than mCRC and breast cancer reached a median sur-
vival of 638 days. The patients who experienced a response or SD
after radioembolization went on to have an increased survival in
comparison to those with progressive disease (604 vs. 251 days;
p= 0.001).
Sato et al. reported a cohort of 131 patients including adrenal,
angiosarcoma, bladder, cervical, duodenal, esophageal, gastric,
lung, lymphoma, ovary, pancreas, parotid, and thyroid cancer, in
addition to the previously discussed primary carcinomas (17). In
their cohort, 90% of patients experienced either a response or
SD by RECIST, an overall rate similar to those reported for more
commonly treated HCC and colorectal metastases.
These experiences suggest that radioembolization may have
application in nearly any liver lesion, whether primary or metasta-
tic disease. It will take time and experience to accumulate data
on each individual tumor type, but as user experience increases,
radioembolization may become a standard offer in patients with
unresectable hepatic disease that is unresponsive to traditional
treatments.
COMPLICATIONS
Radioembolization remains well-tolerated. Post-embolization
syndrome symptoms are common, reported at 67 and 100% (18,
19) by common terminology criteria for adverse events (CTCAE).
Though these symptoms were common, only 18% needed hospi-
talization for one night for pain control or dehydration. These
symptoms are typically managed conservatively and generally
resolve within 1 week. Grade 3 toxicities of nausea, vomiting, and
pain by CTCAE occurred in <20% of patients in the above series
with no deaths attributed to the procedure.
The incidence of radioembolization-induced hepatic failure,
though a valid concern, is minimal, reported as low as 0–4%
(1). The rate of major complications for both radioembolization
and chemoembolization are similar, with one review of metasta-
tic NET compiling 423 patients reporting 0.95% of patient dying
within 30 days of radioembolization. This was secondary to var-
ious reasons including tumor progression as well as one patient
from hepatic failure (1). In similar studies with TACE, 3.2% died
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within 30 days. The most frequent cause, accounting for approx-
imately one-third of these deaths, was hepatic failure due to high
tumor burden resulting in hepatic infarction.
As with radioembolization in HCC and mCRC, absolute con-
traindications to treatment include significant hepatopulmonary
shunting and reflux into arteries that supply the gastroduodenal
artery region, which may result in non-target radiation. This can
lead to gastric or duodenal ulcers, pancreatitis, cholecystitis, or
radiation pneumonitis and emphasizes the importance of the pre-
SIRT procedure in which non-target vessels are embolized prior to
the treatment. Radioembolization-induced hepatic failure, though
rare, remains a concern and may be avoided by treating one lobe
at a time and proper patient selection.
RADIOEMBOLIZATION OUTSIDE THE LIVER
There is interest in using radioembolization outside the traditional
treatment bed of the liver to treat tumors. However, the data is
sparse, and limited to case reports. Therefore, aside from safety
profiles, little conclusions can be made in this realm.
Hamoui et al. describe a case of a patient with a renal mass
who was referred for palliative therapy because of advanced stage
of disease (20). Biopsy had revealed renal cell carcinoma of an
aggressive sarcomatoid subtype. Due to advanced age, systemic
chemotherapy was not an option. The patient was also found to
have liver metastases. The patient subsequently underwent plan-
ning mesenteric and renal angiography and returned 1 week later
for radioembolization of the renal tumor. The authors gave intra-
venous hydration and admitted the patient for observation. She
reported only mild nausea and pain after the procedure, which
were medically controlled. At 8 weeks, CT showed new areas of
necrosis in the renal tumor, which was itself stable in size. The
renal lesion remained stable at 9 months; however was found
to have new pulmonary nodules. The patient died 23 months
after radioembolization. This compares favorably to the expected
survival of sarcomatoid renal cell carcinoma in the range of 3–
10 months. In carefully selected patients, radioembolization may
be a viable option in advanced or metastatic renal cell carcinoma.
Despite public efforts, lung cancer remains a major cause of
cancer related death worldwide. In addition to primary tumors,
metastatic disease to the lung is common. Surgical resection
remains the definitive treatment and thermal ablation is also
becoming a well-established approach. However, these have lim-
ited roles when there are greater than three lesions or if the lesion
is >3 cm. Localized transarterial treatment of lung tumors, with
delivery via the bronchial arteries, is therefore of great interest.
Ricke et al. described Y-90 resin-microspheres treatment to the
lungs in two patients with diffuse metastatic disease of colorectal
and renal cell cancer, respectively (21). The decision was made
to attempt radioembolization in these patients in only a por-
tion of the lung, with the intent of preserving untreated areas
of lung in case of radiation-induced pneumonitis. Lung func-
tion tests remained normal through 4 weeks in both patients and
no evidence of pneumonitis was seen on CT up to 12 weeks
in one patient. Targeted nodules were either stable or showed
partial remission, whereas non-targeted nodules showed progres-
sive disease. The patients, whose disease burden was high before
undergoing the treatment, died at 6 and 9 months, respectively.
Pneumonitis is one of the primary concerns limiting radioem-
bolization in patients with high lung shunt fraction. Interestingly,
neither of the patients in this report demonstrated radiation-
induced lung injury. However, pulmonary function tests were only
carried out to 4 weeks, and radiation effects may take months to
years to develop. Nevertheless, in patients with pulmonary lesions
who have failed traditional therapies, radioembolization may offer
a chance of increased survival.
CONCLUSION
As experience with Y-90 radioembolization grows, there is increas-
ing interest in exploring new applications as reviewed here. These
studies increase the already extensive data supporting the safety
and efficacy of Y-90 radioembolization in various applications.
Head to head, comparative studies are still needed to fully define
the role Y-90 in these emerging uses. The collective experiences
described here and elsewhere suggest a potentially wide ranging
and significant role of Y-90 radioembolization in oncology that is
yet to be realized.
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